Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Active, not recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting125%
active_not_recruiting375%

Recent Activity

3 active trials
Showing 4 of 4
active_not_recruitingphase_1

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

NCT06196827
active_not_recruitingphase_3

Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

NCT07054632
active_not_recruitingphase_1

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

NCT06212297
not_yet_recruitingnot_applicable

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

NCT06024057

Clinical Trials (4)

Showing 4 of 4 trials
NCT06196827Phase 1

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Active Not Recruiting
NCT07054632Phase 3

Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Active Not Recruiting
NCT06212297Phase 1

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Active Not Recruiting
NCT06024057Not Applicable

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
4